Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

Blood

Volumn 114, Issue 16, 2009, Pages 3431-3438

  Houot, Roch ^a   Goldstein, Matthew J ^a   Kohrt, Holbrook E ^a   Myklebust, June H ^a   Alizadeh, Ash A ^a   Lin, Jack T ^a   Irish, Jonathan M ^a   Torchia, James A ^a   Kolstad, Arne ^b   Chen, Lieping ^c   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; UNCLASSIFIED DRUG; CD137 ANTIGEN; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VIVO STUDY; MANTLE CELL LYMPHOMA; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; DRUG POTENTIATION; DRUG SCREENING; IMMUNOLOGY; LYMPHOCYTE DEPLETION; LYMPHOMA; MALE; METHODOLOGY; NATURAL KILLER CELL; PASSIVE IMMUNIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOLOGIC FACTORS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; LYMPHOMA; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, REGULATORY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350713055     PISSN: 00064971     EISSN: 15280020     Source Type: None    
DOI: 10.1182/blood-2009-05-223958     Document Type: Article

References (38)

1. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol. 2005;23(26):6421-6428. (Pubitemid 46218853)
2. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5(4):263-274. (Pubitemid 40488632)
3. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95-106. (Pubitemid 46160986)
4. Murillo O, Arina A, Tirapu I, et al. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin Cancer Res. 2003;9(15):5454-5464. (Pubitemid 37499463)
5. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med. 2008;205(4):825-839. (Pubitemid 351549881)
6. Shevach EM, Stephens GL. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol. 2006;6(8):613-618.
7. Sugamura K, Ishii N,Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol. 2004;4(6):420-431. (Pubitemid 38745554)
8. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105(7):2845-2851. (Pubitemid 40446278)
9. Vu MD, Xiao X, Gao W, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110(7):2501-2510. (Pubitemid 47523172)
10. Melero I, Murillo O, Dubrot J, Hervas-Stubbs S, Perez-Gracia JL. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 2008;29(8):383-390.
11. Choi BK, Bae JS, Choi EM, et al. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol. 2004;75(5):785-791.
12. Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol. 2007;179(11):7295-7304.
13. Robertson SJ, Messer RJ, Carmody AB, Mittler RS, Burlak C, Hasenkrug KJ. CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol. 2008;180(8):5267-5274.
14. Zheng G, Wang B, Chen A. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J Immunol. 2004;173(4):2428-2434.
15. Murillo O, Arina A, Hervas-Stubbs S, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res. 2008;14(21):6895-6906.
16. Ramaswamy S, Tamayo P, Rifkin R, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001;98(26):15149-15154. (Pubitemid 34013984)
17. International Genomics Corporation. expO. https://expo.intgen.org/geo/ home.do. Accessed May 20, 2009.
18. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6:1-6. (Pubitemid 38391943)
19. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www.ncbi.nlm.nih.gov/geo. Accessed May 20, 2009.
20. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006; 108(9):3135-3142. (Pubitemid 44776954)
21. Stokke T, Galteland E, Holte H, et al. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer. 2000;89(4):313-324. (Pubitemid 30620283)
22. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest. 2002;109(5):651-659. (Pubitemid 34204844)
23. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514-5521. (Pubitemid 30761266)
24. Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005;202(7):885-891. (Pubitemid 41396888)
25. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
26. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27(1):145-159. (Pubitemid 47089022)
27. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles: database and tools update. Nucleic Acids Res. 2007;35:D760-D765. (Pubitemid 46056306)
28. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113(15):3546-3552.
29. Zhang B, Maris CH, Foell J, et al. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest. 2007;117(10):3029-3041. (Pubitemid 47529632)
30. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 1998;190(2):167-172. (Pubitemid 29011104)
31. Wilcox RA, Tamada K, Strome SE, Chen L. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol. 2002;169(8):4230-4236. (Pubitemid 35178194)
32. Umetsu DT, Esserman L, Donlon TA, DeKruyff RH, Levy R. Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones. J Immunol. 1990;144(7):2550-2557. (Pubitemid 20136656)
33. Choi BK, Kim YH, Kang WJ, et al. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 2007;67(18):8891-8899.
34. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108(9):2957-2964. (Pubitemid 44776932)
35. Lee NR, Song EK, Jang KY, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49(2):247-256.
36. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4+ CD25+ regulatory T cells. J Immunol. 2005;175(7):4180-4183.
37. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood. 2006;107(10):3925-3932.
38. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol. 2007;178(11):6840-6848. (Pubitemid 46847409)